These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18813182

  • 1. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients.
    Farah R, Shurtz-Swirski R.
    Minerva Cardioangiol; 2008 Oct; 56(5):467-76. PubMed ID: 18813182
    [Abstract] [Full Text] [Related]

  • 2. [The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients].
    Shurtz-Swirski R, Farah R, Sela S, Shapiro G, Klempef R, Snitkovski T, Kristal B.
    Harefuah; 2006 Dec; 145(12):895-9, 942. PubMed ID: 17220028
    [Abstract] [Full Text] [Related]

  • 3. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients.
    Farah R, Khamisy-Farah R, Shurtz-Swirski R.
    Int Angiol; 2013 Feb; 32(1):85-93. PubMed ID: 23435396
    [Abstract] [Full Text] [Related]

  • 4. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients: effect of statins.
    Farah R, Shurtz-Swirski R, Dorlechter F.
    Minerva Cardioangiol; 2010 Apr; 58(2):175-81. PubMed ID: 20440247
    [Abstract] [Full Text] [Related]

  • 5. Oxidative stress and inflammation due to peripheral polymorphonuclear leukocytes after coronary angiography vs percutaneous coronary intervention.
    Farah R, Shurtz-Swirski R, Bolotin Y, Brezins M.
    Minerva Cardioangiol; 2008 Apr; 56(2):189-95. PubMed ID: 18319697
    [Abstract] [Full Text] [Related]

  • 6. Lercanidipine effect on polymorphonuclear leukocyte-related inflammation and insulin resistance in essential hypertension patients.
    Farah R, Shurtz-Swirski R, Khamisy-Farah R.
    Cardiol Ther; 2012 Dec; 1(1):4. PubMed ID: 25135158
    [Abstract] [Full Text] [Related]

  • 7. [Polymorphonuclear leukocyte priming and counts are in correlation with blood pressure parameters].
    Mazor R, Shurtz-Swirski R, Sela S, Shapiro G, Kristal B.
    Harefuah; 2006 Dec; 145(12):900-3, 941. PubMed ID: 17220029
    [Abstract] [Full Text] [Related]

  • 8. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease.
    Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B.
    J Am Soc Nephrol; 2005 Aug; 16(8):2431-8. PubMed ID: 15987755
    [Abstract] [Full Text] [Related]

  • 9. Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension.
    Rodrigo R, Prat H, Passalacqua W, Araya J, Bächler JP.
    Clin Sci (Lond); 2008 May; 114(10):625-34. PubMed ID: 17999638
    [Abstract] [Full Text] [Related]

  • 10. Reactive oxygen species and antioxidant status in essential arterial hypertension during therapy with dihydropyridine calcium channel antagonists.
    Digiesi V, Fiorillo C, Cosmi L, Rossetti M, Lenuzza M, Guidi D, Pace S, Rizzuti G, Nassi P.
    Clin Ter; 2000 May; 151(1):15-8. PubMed ID: 10822876
    [Abstract] [Full Text] [Related]

  • 11. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients.
    Mazor R, Shurtz-Swirski R, Farah R, Kristal B, Shapiro G, Dorlechter F, Cohen-Mazor M, Meilin E, Tamara S, Sela S.
    Atherosclerosis; 2008 Apr; 197(2):937-43. PubMed ID: 17869258
    [Abstract] [Full Text] [Related]

  • 12. Effects of statins on oxidative stress and primed polymorphonuclear leukocytes in hyperlipidemic patients.
    Farah R, Jubran F, Khamisy-Farah R.
    Biotech Histochem; 2012 Nov; 87(8):519-25. PubMed ID: 22989353
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of psychosomatic symptomatology in hypertensive patients treated with lercanidipine (LERCAPSICO study)].
    Abellán Alemán J, Martínez García JF, Merino Sánchez J, Gil Guillén V, Latorre Hernández J, Fernández Montero F, Navarro Lima A, Grupo de Investigaciones del Estudio LERCAPSICO.
    An Med Interna; 2003 Jun; 20(6):287-91. PubMed ID: 12848598
    [Abstract] [Full Text] [Related]

  • 14. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
    Cicero AF, Gerocarni B, Rosticci M, Borghi C.
    Clin Exp Hypertens; 2012 Jun; 34(2):113-7. PubMed ID: 21967031
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of lercanidipine in the general practice setting].
    Robles NR, Canelada JA, Iglesias M, Angulo E, López Acedo A, Díaz Olea E, Cidoncha F, Guerras M, Fuentes J, Garrido J, Lapie J, Peña J, Aguilar A, Hidalgo P.
    An Med Interna; 2003 Jun; 20(6):282-6. PubMed ID: 12848597
    [Abstract] [Full Text] [Related]

  • 16. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
    Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ.
    Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181
    [Abstract] [Full Text] [Related]

  • 17. Lercanidipine in patients with chronic renal failure: the ZAFRA study.
    Robles NR, Ocon J, Gomez CF, Manjon M, Pastor L, Herrera J, Villatoro J, Calls J, Torrijos J, Rodríguez VI, Rodriguez MM, Mendez ML, Morey A, Martinez FI, Marco J, Liebana A, Rincon B, Tornero F.
    Ren Fail; 2005 Jan; 27(1):73-80. PubMed ID: 15717638
    [Abstract] [Full Text] [Related]

  • 18. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T.
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [Abstract] [Full Text] [Related]

  • 19. Elevation of serum soluble E- and P-selectin in patients with hypertension is reversed by benidipine, a long-acting calcium channel blocker.
    Sanada H, Midorikawa S, Yatabe J, Yatabe MS, Katoh T, Baba T, Hashimoto S, Watanabe T.
    Hypertens Res; 2005 Nov; 28(11):871-8. PubMed ID: 16555575
    [Abstract] [Full Text] [Related]

  • 20. Lercanidipine in the treatment of hypertension.
    Beckey C, Lundy A, Lutfi N.
    Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.